11 It is recommended that patients with PAD and type 2 diabetes should be given an SGLT-2 inhibitor versus usual diabetes control, since MACE is reduced, without any risk of increased amputation rate. The gene discussed is SLC5A2; the disease is peripheral arterial disease.